about the author

Kyle Blankenship

kyle@endpointsnews.com @ka_blankenship
Kyle Blankenship on LinkedIn

author articles

With FDA fil­ing for key gene ther­a­py pushed back 6 months, uniQure opens the pock­et­book to re­fresh the pipeline

4 years ago
Deals
FDA+

Mer­ck­'s Keytru­da blazes a path in first-line cer­vi­cal can­cer, mak­ing good on drug­mak­er's push for ear­li­er pa­tients

4 years ago
R&D
Pharma

Big Phar­ma back­ers jump on board 'Treg' car­tog­ra­pher's lead round with up to six can­di­dates in the pipe

4 years ago
Financing

The dig­i­tal health field con­tin­ues to boom as Soft­Bank-backed start­up hits uni­corn sta­tus in SPAC re­verse merg­er

4 years ago
Financing
Deals

Or­phan drug spe­cial­ist Hori­zon looks to dou­ble down on its gout ex­per­tise with ac­quired rights to Ar­row­head­'s RNAi ...

4 years ago
Deals

Who are the lu­mi­nar­ies dri­ving the biggest ad­vances in bio­phar­ma R&D? End­points News is ask­ing for your nom­i­na­tions ...

4 years ago
R&D

Hutchmed files for $600M+ IPO in Hong Kong as lead on­col­o­gy drug su­r­u­fa­tinib awaits FDA's good graces

4 years ago
Financing
China

Bris­tol My­ers breaks the bank on Ei­sai's fo­late re­cep­tor ADC drug, lay­ing out more than $3B+ for rights

4 years ago
Deals

As it awaits piv­otal re­view of lead drug, Fi­bro­Gen bol­sters its ear­ly pipeline with li­cens­ing deal for galectin ...

4 years ago
Deals

A re­place­ment for read­ing glass­es? An RA, Ver­sant-backed start­up thinks its eye­drops could solve far­sight­ed­ness

4 years ago
Financing
Startups

Chi­nese on­col­o­gy spe­cial­ist Zai Lab bro­kers a deal with Macro­Gen­ics for up to 4 bis­pecifics with a mod­est down ...

4 years ago
Deals

Is­rael's VBL Ther­a­peu­tics hit with CMC de­lays in ovar­i­an can­cer study; No­vo Hold­ings buys out di­ag­nos­tics play­er BBI

4 years ago
News Briefing

CRISPR Ther­a­peu­tics takes a swing at ALS gene edit­ing in dis­cov­ery deal with AAV up­start Cap­si­da

4 years ago
Deals

Months af­ter FDA re­jec­tion, Sanofi touts piv­otal win for rare dis­ease drug su­tim­limab as it preps to re­file

4 years ago
R&D
Pharma

No­var­tis cuts jobs at Swiss plant as a UK fa­cil­i­ty sits in a hold­ing pat­tern with 200 po­si­tions on the line — ...

4 years ago
Outsourcing
Manufacturing

Bris­tol My­er­s' CAR-T Breyanzi busts out a win in ear­li­er-line lym­phoma, po­ten­tial­ly crack­ing open an ex­pand­ed mar­ket

4 years ago
R&D
Pharma

Sid Mukher­jee's Vor taps a CAR-T de­vel­op­ment part­ner to strap to its at­tempt at bet­ter stem cell trans­plants

4 years ago
Deals
Cell/Gene Tx

A Medicxi-backed start­up looks to tack­le treat­ment-re­sis­tant blood can­cers, and it's go­ing af­ter AML first

4 years ago
Financing
Startups

Vi­a­Cyte adds to the war chest in what looks like an IPO-bound ef­fort to bring re­gen­er­a­tive med­i­cine to di­a­betes

4 years ago
Financing
Cell/Gene Tx

BeiGene dives in on nat­ur­al killer cells with dis­cov­ery pact for small biotech's stem cell-based plat­form

4 years ago
Deals

A Cell­tri­on-backed biotech is de­vel­op­ing 'tun­able' con­ju­gates to crack sol­id tu­mors — and it has eyes on the clin­ic

4 years ago
Financing

#AS­CO21: Gilead­'s Trodelvy reads out new sub­group da­ta show­ing ben­e­fit in ear­li­er-line TNBC pa­tients

4 years ago
R&D

#AS­CO21: Co­herus, Jun­shi hunt US ap­proval for an­ti-PD-1 drug in nose and throat can­cer with late-stage win

4 years ago
R&D

#AS­CO21: Bris­tol My­er­s' so­lo, dual I/O reg­i­mens best chemo alone — with one ex­cep­tion — in first-line esophageal ...

4 years ago
R&D
First page Previous page 891011121314 Next page Last page
A service from the Financial Times